Malunggary herbal medicine is one of the most commonly used herbal medicines in India.
It is also widely used by people with cancer, diabetes, HIV, and other illnesses.
In 2015, it was declared the most effective chemotherapy agent in the world by the European Cancer Society (ECSS).
But it is also associated with a range of adverse reactions including skin irritation, liver damage, gastrointestinal problems, and even cancer.
In addition, the drug is frequently prescribed to those who suffer from chemotherapy-induced nausea and vomiting.
Now, a new study by a team of researchers in India and the US shows that malunigay herbal medicines have an increased risk of toxicity and side effects associated with chemotherapy.
According to the new study, the risk of side effects and toxicity increases after prolonged use.
The researchers say that people taking malunuggay herbal medications should be aware of the potential side effects that might arise as they continue to use them for a prolonged period of time.
They are also recommending that people who are undergoing chemotherapy or who are considering undergoing chemotherapy for the first time consider whether malunnggay herbs can help them cope with the long-term effects of chemotherapy.
The findings have been published in the journal ACS Chemother.
The team of research team conducted the study after conducting a study on malunaggay herb in combination with chemotherapy agents.
According the authors, malunonggay, which is known as a combination of a plant and an herb, has been used in India for decades.
It has been known for its powerful anti-cancer properties, and its use is highly regulated.
However, in recent years, the use of malunoggay has been increasing due to the fact that the drug has a wider range of medicinal properties.
The authors of the study say that maluriggay is currently the most widely used herbal medicine in India, and in some countries, it has become the most prescribed chemotherapy drug.
The study found that the use by malunanggay patients increased after chemotherapy began, which was associated with an increased overall risk of adverse events and toxicity.
They also found that chemotherapy-associated nausea and severe vomiting was more common among malunango patients.
The group also noted that malunaiggaggai was a relatively safe alternative to malunugaiggai, which has a lower efficacy rate.
However that is still a safe option for the majority of malunaigs, the researchers say.
The next step will be to assess whether malungaggaga and malununggaga may be able to be used to treat chemotherapy-related nausea and pain after long-lasting chemotherapy, they add.
“These are promising findings and could potentially pave the way for the development of safer and more effective chemotherapy agents,” said lead author Dr. M. A. Gupta of the Center for Bioeconomics at the University of California, San Francisco, in a press release.
“As we continue to develop novel and effective chemotherapies, we need to develop safe and effective herbal products to support this progress.”
Malunuggi, which means green or green-eyed flower, is also used to control diarrhea, fever, and gas in certain parts of the world.
The herb is a type of medicinal plant and is usually harvested from the stems of the plant.
According in the study, there are several compounds in malunugu that may interact with chemotherapy-sensitive proteins, such as those of the human and human breast cancer cells, which are also present in the liver.
The compounds may result in changes in the cells that may lead to liver toxicity and death.
This is a first step toward finding the best drugs for treating cancer, said Gupta.
The other authors are Dr. Anuja Varma, Dr. T. P. Shah, and Dr. Prashant Bhatia of the Department of Pharmacology, University of Pennsylvania, and Prof. V. Rajesh Rao of the School of Pharmacy and Biochemistry, IIT Delhi.
The research was supported by the National Institutes of Health and the National Cancer Institute (NCI) through its National Center for Cancer Research (NCR) Program in Cancer Research, and the Office of Naval Research (ONR) Office of Biological Research and Development (BIRD) Program.
The IITs Center for Biological Sciences (CBS) and the College of Pharmaceutics and Pharmaceutical Sciences at the Indian Institute of Technology Bombay (IIT-Bombay) were also involved in the research.
The University of Texas Health Science Center at Houston also supported the study.
ACS Chemotherapy is a joint effort between the U.S. National Institutes on Drug Abuse (NIDA) and The National Cancer Institutes (NCRI).